

momentum, driven by the extensive datasets on better radial access outcomes to encourage the next generation of interventionalists to step to the front of the world's stage in patient care.

*Morton J. Kern, MD

*University of California, Irvine
Building 53, Route 81, Room 100
101 The City Drive
Orange, California 92868
E-mail: mkern@uci.edu

doi:10.1016/j.jcin.2009.11.011

REFERENCE

1. Kern MJ. Cardiac catheterization on the road less traveled: navigating the radial versus femoral debate. *J Am Coll Cardiol Intv* 2009;2:1055-6.

Phenotypes, Genotypes, and the 9p21 Locus for Prediction of Cardiovascular Events

I would like to commend Hoppmann et al. (1) for their thorough and well-executed paper. In this regard, I agree with the editorial by Horne and Anderson (2) that discusses the importance of the Hoppmann et al. (1) study. Thoughtfully executed prospective studies that attempt to clinically examine genomic data first identified in genome-wide association studies are at a premium.

Other remarks in the editorial by Horne and Anderson (2) are a source of disagreement. First, the authors make the argument that because replications of the 9p21 single nucleotide polymorphisms (SNPs) have been done in populations that suffer from both documented coronary artery disease (CAD) and myocardial infarction (MI), these individual phenotypes—when grouped together—confound the type of risk (phenotype) that can be attributed to these genetic factors. Although their argument is understood, it is important to point out that on the basis of experience, these genetic markers are statistically significant in both subpopulations to sometimes nearly equal extent. These data are sometimes not shown in final reports and are only rarely shown in supplemental data. The authors then attempt to differentiate the pathogenesis of CAD and that of MI as 2 distinct entities, which further precludes attribution of genetic risk to either of those 2 phenotypes individually. It is difficult to assume that the well-known progression of CAD to MI (barring less usual suspects such as spasm or dissection) can be so thoroughly extricated from each other as to invalidate the dozens of studies that have replicated the 9p21 locus as a risk marker for CAD and MI.

The authors then make the argument that because the study by Hoppmann et al. (1) finds there to be a negative association between restenosis and these genomic markers, restenosis must be

a distinct pathophysiologic entity from CAD because it is not “driven” by genetic factors at 9p21.3. Though this might be the case as evidenced by much work in cell biology and immunology, an assumption based on 1 prospective clinical study that examined 4 SNPs is difficult to accept. Additionally, it should be noted that the 4 SNPs tested by Hoppmann et al. (1) are not the most frequently validated SNPs for 9p21 but rather an amalgam of SNPs from different studies that first identified the variants. This is possibly due to the initiation of the 3-year prospective study before replications of the more popular variants in better-characterized populations.

It is certainly necessary to temper our enthusiasm for direct-to-consumer genetic testing until these markers can be better understood, a point of agreement with Horne and Anderson (2). In the interim, we should encourage more studies such as the one presented by Hoppmann et al. (1) and continue our emphasis on preventative cardiovascular medicine.

*Kalil G. Abdullah, BS

*Cleveland Clinic
Lerner College of Medicine
Howard Hughes Medical Institute
Office of Grants and Special Programs
1 Cloister Court
Bethesda, Maryland 20814
E-mail: abdullk@ccf.org

doi:10.1016/j.jcin.2009.12.005

REFERENCES

1. Hoppmann P, Erl A, Turk S, et al. No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents. *J Am Coll Cardiol Intv* 2009;2:1149-55.
2. Horne BD, Anderson JL. Irrelevance of the chromosome 9p21.3 locus for acute cardiovascular events and restenosis. *J Am Coll Cardiol Intv* 2009;2:1156-7.

Reply

We would like to thank Dr. Abdullah for the remarks regarding our editorial (1). We appreciate the subtleties of our assertions and acknowledge that the important biological distinctions among myocardial infarction (MI), coronary artery disease (CAD), and restenosis might be unfamiliar. We appreciate the opportunity to clarify our arguments.

It was not our intent to claim that prior studies associating 9p21.3 with MI risk are invalid but to say that some erroneous conclusions about pathophysiological implications for coronary heart disease were drawn from those landmark studies. Because restenosis is a different process than CAD (2), our intent also was to note that 9p21.3 is not involved in its distinctive pathophysiology (1).

A major component of our argument is, in fact, that 9p21.3 single nucleotide polymorphisms “are statistically significant in both subpopulations to sometimes nearly the same extent.” To illustrate, consider 1 European study that showed a similar effect

size for comparisons of a 9p21.3 single nucleotide polymorphisms in the MI versus normal control subjects and CAD versus normal control subpopulations (3). On further analysis of those data for just MI versus CAD cases (4), the frequency of the risk allele among the MI cases was not higher than for CAD cases.

We also demonstrated the lack of 9p21.3 association with MI per se in 2 U.S. population samples (4). Data from other centers also demonstrate the same lack of association for MI compared with CAD cases (5), although MI versus control and CAD versus control are significant in those studies.

Coronary heart disease is a multistage process, with the development of CAD first (which 9p21.3 specifically affects) and followed sometimes by the precipitation of MI (via plaque instability and thrombosis, which 9p21.3 does not influence). Overall, 9p21.3 does predict "MI status" if control subjects are CAD-free but provides no information about MI risk per se. It is our proposal, thus, that 9p21.3 predicts atherosclerosis (which MI patients have experienced) and not MI precipitation.

***Benjamin D. Horne, PhD, MPH**

Jeffrey L. Anderson, MD

*Cardiovascular Department

Intermountain Medical Center
Genetic Epidemiology Division
Department of Biomedical Informatics
University of Utah
5121 South Cottonwood Street
Salt Lake City, Utah 84107
E-mail: benjamin.horne@imail.org

doi:10.1016/j.jcin.2009.12.004

REFERENCES

1. Horne BD, Anderson JL. Irrelevance of the chromosome 9p21.3 locus for acute cardiovascular events and restenosis. *J Am Coll Cardiol Intv* 2009;2:1156-7.
2. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. *Circulation* 2005;111:2257-73.
3. Schunkert J, Götz A, Braund P, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. *Circulation* 2008;117:1675-84.
4. Horne BD, Carlquist JF, Muhlestein JB, Bair TL, Anderson JL. Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. *Circ Cardiovasc Genet* 2008;1:85-92.
5. Dandona S, Stewart AFR, Chen L, et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. *J Am Coll Cardiol* 2010. In press.